PPT-Dual Antiretroviral Therapy

This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, NW AETC ECHO. Last Updated. : April 16, 2015. Source: . HHS . Antiretroviral Therapy Guidelines. . AIDS Info (www.aidsinfo.nih.gov). Moderator. François Raffi, MD, PhD. Professor of Infectious and . Tropical Diseases . University of Nantes . Nantes, France . Panelists. Chloe Orkin, MD, FRCP . Professor of HIV Medicine . Grahame Hayton Unit. Simi Padival, MD. November 3, 2016. Objectives. Learn about the importance of assessing adherence to antiretroviral therapy (ART). Learn about the components of assessing for ART adherence. Discuss frequency of monitoring while on ART. Module 10:. Pharmacovigilance. Background – definitions. Timeline of pharmacovigilance for a drug from development (pre-market) to post-marketing use. Burden of adverse drug reactions in children. Number of pharmacoepidemiological safety studies in children (Osokogu et al, 2016). Camille Angle, Meagan Bardan, Hanna Schimjawicz and Sean Tabarah. PHM142 Fall . 2018. Instructor: . Ms. Maya Latif. Coordinator: Dr. J. Henderson. HIV Attachment and Penetration. Wilen, C. B., Tilton, J. C., & Doms, R. W. D. (2012). HIV: Cell binding and entry. . implementation of Dolutegravir. Meireles MV. , Pascom ARP, Perini F, Rick F, Benzaken A. . Ministry of Health of Brazil, Department of STI, AIDS and Viral Hepatitis. Acknowledgements. No. . conflicts of interest. ACTIVITY CODE . TD342. Antiretroviral Medications: . What . you need to know. Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP. Associate Professor, Department of Pharmacy Practice. Joseph J. Eron, Jr, MD Professor of Medicine and Epidemiology The University of North Carolina at Chapel Hill Chapel Hill, North Carolina Future Directions: Investigational Approaches to Antiretroviral Therapy . Trikudanathan. , MD, MRCP, . MMSc. Division of Endocrinology, Metabolism and Nutrition. University of Washington Medical Center. Presentation prepared by: . S. . Trikudanathan. Presenter: S. . Trikudanathan. The University of North Carolina at Chapel Hill. Chapel Hill, North Carolina. Future Directions: Investigational Approaches to Antiretroviral Therapy. Washington, DC: . August . 24, . 2016. . Future Directions: . 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. A5173 Study. Intensive . Enfuvirtide. -containing Antiretroviral Therapy . A5173: . Study Design. Source: Gandhi RT, et al. . J . Infect. . Dis. . . 2010;201(2. ):293-6.. Enfuvirtide. +. TDF + (FTC or 3TC) +. therapy. . on. . the. CD4/CD8 ratio and CD8 . cell. . counts. in . CoRIS. : . a . prospective. . multicentre. . cohort. . study. .. Serrano-Villar S, et al. . Lancet. HIV 2020; 7: e565-73. Juan E. Losa. With Emergence of Comorbidities. Roger J. . Bedimo. , MD. Professor of Medicine. University of Texas Southwestern Medical Center. Dallas, TX. Learning Objectives. On completion of this presentation, learners will be able to:.